Safety and efficacy of reduced-intensity myeloablative conditioning regimen with fludarabine and intravenous busulfan for hematological malignancies

Safety and efficacy of reduced-intensity myeloablative conditioning regimen with fludarabine and intravenous busulfan for hematological malignancies - Safety and efficacy of reduced-intensity myeloablative conditioning regimen with fludarabine and intravenous busulfan for hematological malignancies

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006540

Enrollment

Registered

2011-10-27

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

Conditioning regimen: Fludarabine 180mg/m2 + intravenous Busulfan 12.8mg/kg + TBI 2Gy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases applicable to reduced-intensity conditioning regimen (age > 55 or having comorbidity)

Exclusion criteria

Exclusion criteria: Those who are considered as inappropriate to register by attending physicians

Design outcomes

Primary

Measure	Time frame
Disease-free survival at 100 days after transplantation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026